Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 25 Nov 2020
Rinvoq continues to be part of the high-cost protection with limited subsidy after reconsideration
25 November 2020 - TLV has reconsidered the subsidy for Rinvoq (upadacitinib monohydrate) and decided that the drug should continue to ...
Posted by Michael Wonder on 25 Nov 2020
NICE publishes final guidance on Nubeqa
25 November 2020 - NICE has completed its assessment of darolutamide for use in combination with androgen deprivation therapy for ...
Posted by Michael Wonder on 25 Nov 2020
Russia looks to undercut rivals with cut-price COVID-19 vaccine
24 November 2020 - Phase 3 trials showed the jab was 91.4% effective in protecting people from COVID-19. ...
Posted by Michael Wonder on 25 Nov 2020
AstraZeneca gears up to vaccinate the world against COVID-19
24 November 2020 - Among the front-runners racing to deliver a COVID-19 shot, has the least vaccine experience. But it has ...
Posted by Michael Wonder on 25 Nov 2020
Liquidia receives complete response letter from FDA for LIQ861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension
25 November 2020 - Complete response letter does not cite need for additional clinical studies. ...
Posted by Michael Wonder on 25 Nov 2020
Remdesivir (Veklury) approval for the treatment of COVID-19—the evidence for safety and efficacy
26 November 2020 - Under FDA law, approval of a new drug requires substantial evidence of effectiveness and a demonstration of ...
Posted by Michael Wonder on 25 Nov 2020
U.S. officials plan to release 6.4 million COVID-19 vaccine doses in first distribution
25 November 2020 - U.S. officials said on Tuesday they plan to release 6.4 million COVID-19 vaccine doses nationwide in ...
Posted by Michael Wonder on 25 Nov 2020
Medical trial delays see Australians wait for rare disease treatment
25 November 2020 - Patients with rare diseases are entering ‘random lottery’ draws for clinical trials because Australia is too slow ...
Posted by Michael Wonder on 25 Nov 2020
Third major COVID-19 vaccine shown to be effective and cheaper
24 November 2020 - Drugmaker AstraZeneca said late-stage trials showed its COVID-19 vaccine is highly effective, buoying the prospects of a ...
Posted by Michael Wonder on 25 Nov 2020
Pfizer vaccine distribution could kick off within weeks pending FDA approval, Azar says
24 November 2020 - A FDA panel will meet on 10 December to consider Pfizer’s emergency use authorisation application for its ...
Posted by Michael Wonder on 25 Nov 2020
EU drug regulator could rule on COVID-19 vaccines by year end
24 November 2020 - The EMA could produce a scientific opinion on COVID-19 vaccines seeking regulatory approval by the end ...
Posted by Michael Wonder on 25 Nov 2020
Bristol Myers Squibb receives European Commission approval for Opdivo (nivolumab) as second-line treatment for unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma
24 November 2020 - First immunotherapy to be approved for a gastro-esophageal cancer in the European Union. ...
Posted by Michael Wonder on 24 Nov 2020
Australia's coronavirus vaccination program to start from March
25 November 2020 - The federal government says Australia is on track to deliver the first vaccines in March. ...
Posted by Michael Wonder on 24 Nov 2020
Doctors say CDC should warn people the side effects from COVID vaccine shots won’t be ‘a walk in the park’
23 November 2020 - The CDC must be transparent about the side effects people may experience after getting their first shot ...
Posted by Michael Wonder on 24 Nov 2020
'Disappointing' delay for new type 2 diabetes drugs that stop kidney failure and save lives
24 November 2020 - Kim Dennis is one of few New Zealanders who knows what it’s like to manage their ...